Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells

Epratuzumab has demonstrated therapeutic activity in patients with non-Hodgkin lymphoma, acute lymphoblastic leukemia, systemic lupus erythematosus, and Sjögren's syndrome, but its mechanism of affecting normal and malignant B cells remains incompletely understood. We reported previously that e...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chien-Hsing, Wang, Yang, Gupta, Pankaj, Goldenberg, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622945/
https://www.ncbi.nlm.nih.gov/pubmed/25484043
http://dx.doi.org/10.4161/19420862.2014.979081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622945/
https://www.ncbi.nlm.nih.gov/pubmed/25484043
http://dx.doi.org/10.4161/19420862.2014.979081

Ejemplares similares